10 likes | 95 Views
The study reveals that MeCP2 restoration in GFAP+ astrocytes through TAM treatment ameliorates symptoms in Mecp2 mutant mice. This finding sheds light on potential therapeutic targets for Rett syndrome.
E N D
MeCP2 is restored specifically in GFAP+ astrocytes of TAM-treated Mecp2Stop/y-hGFAPcreT2 mice. DT Lioy et al.Nature000, 1-4 (2011) doi:10.1038/nature10214